Hong Kong Stocks Movement | GIANT BIOGENE (02367) Rebounds Over 6% as Approved Recombinant Collagen Medical Aesthetic Product Expected to Drive Second Growth Curve

Stock News11-10

GIANT BIOGENE (02367) rebounded more than 6%. At the time of writing, the stock rose 4.1% to HK$40.1, with a turnover of HK$411 million.

In October this year, the company's first Class III medical aesthetic product—recombinant type I a1 collagen freeze-dried fiber—was approved for filling facial dermal tissue to correct dynamic forehead wrinkles, including glabellar lines, forehead lines, and crow's feet. Additionally, the company currently has three medical aesthetic products under development, including facial hydration, neck wrinkle treatment, and volumizing fillers.

Analysts noted that due to public sentiment, livestreaming sales structure, and competition, the ranking of its flagship brand "Kefumei" declined during the Double 11 shopping festival, potentially putting short-term pressure on its skincare business. However, the company's strong brand equity and operational foundation remain intact, with focus on subsequent channel adjustments and new product launches.

Furthermore, recombinant collagen is recognized for its anti-aging and reparative properties, with strong consumer awareness. Given the company's established presence in the medical aesthetic channel, the newly approved product is expected to contribute to a second growth curve post-launch.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1146543306?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 11:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1146543306","market":"other","top_or_hot":-1,"title":"Hong Kong Stocks Movement | GIANT BIOGENE (02367) Rebounds Over 6% as Approved Recombinant Collagen Medical Aesthetic Product Expected to Drive Second Growth Curve","media":"Stock News","content":"<p>GIANT BIOGENE (02367) rebounded more than 6%. At the time of writing, the stock rose 4.1% to HK$40.1, with a turnover of HK$411 million.</p>\n<p>In October this year, the company's first Class III medical aesthetic product—recombinant type I a1 collagen freeze-dried fiber—was approved for filling facial dermal tissue to correct dynamic forehead wrinkles, including glabellar lines, forehead lines, and crow's feet. Additionally, the company currently has three medical aesthetic products under development, including facial hydration, neck wrinkle treatment, and volumizing fillers.</p>\n<p>Analysts noted that due to public sentiment, livestreaming sales structure, and competition, the ranking of its flagship brand \"Kefumei\" declined during the Double 11 shopping festival, potentially putting short-term pressure on its skincare business. However, the company's strong brand equity and operational foundation remain intact, with focus on subsequent channel adjustments and new product launches.</p>\n<p>Furthermore, recombinant collagen is recognized for its anti-aging and reparative properties, with strong consumer awareness. Given the company's established presence in the medical aesthetic channel, the newly approved product is expected to contribute to a second growth curve post-launch.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stocks Movement | GIANT BIOGENE (02367) Rebounds Over 6% as Approved Recombinant Collagen Medical Aesthetic Product Expected to Drive Second Growth Curve</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stocks Movement | GIANT BIOGENE (02367) Rebounds Over 6% as Approved Recombinant Collagen Medical Aesthetic Product Expected to Drive Second Growth Curve\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-10 11:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GIANT BIOGENE (02367) rebounded more than 6%. At the time of writing, the stock rose 4.1% to HK$40.1, with a turnover of HK$411 million.</p>\n<p>In October this year, the company's first Class III medical aesthetic product—recombinant type I a1 collagen freeze-dried fiber—was approved for filling facial dermal tissue to correct dynamic forehead wrinkles, including glabellar lines, forehead lines, and crow's feet. Additionally, the company currently has three medical aesthetic products under development, including facial hydration, neck wrinkle treatment, and volumizing fillers.</p>\n<p>Analysts noted that due to public sentiment, livestreaming sales structure, and competition, the ranking of its flagship brand \"Kefumei\" declined during the Double 11 shopping festival, potentially putting short-term pressure on its skincare business. However, the company's strong brand equity and operational foundation remain intact, with focus on subsequent channel adjustments and new product launches.</p>\n<p>Furthermore, recombinant collagen is recognized for its anti-aging and reparative properties, with strong consumer awareness. Given the company's established presence in the medical aesthetic channel, the newly approved product is expected to contribute to a second growth curve post-launch.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999004311.SGD","symbol_name":"Nikko AM Shenton Emerging Enterprise Discovery Fund SGD","start_time":0,"source_url":"","article_id":"1146543306","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1146543306","pubTimestamp":1762746014,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"GIANT BIOGENE (02367) rebounded more than 6%. At the time of writing, the stock rose 4.1% to HK$40.1, with a turnover of HK$411 million. In October this year, the company's first Class III medical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999004311.SGD":"Nikko AM Shenton Emerging Enterprise Discovery Fund SGD","02367":"巨子生物","BK1207":"个人用品","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC"},"translate_title":"港股动向|巨人生物基因(02367)反弹超6%重组胶原蛋白医美产品获批有望带动第二增长曲线","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02367":1},"content_text":"GIANT BIOGENE (02367) rebounded more than 6%. At the time of writing, the stock rose 4.1% to HK$40.1, with a turnover of HK$411 million.\nIn October this year, the company's first Class III medical aesthetic product—recombinant type I a1 collagen freeze-dried fiber—was approved for filling facial dermal tissue to correct dynamic forehead wrinkles, including glabellar lines, forehead lines, and crow's feet. Additionally, the company currently has three medical aesthetic products under development, including facial hydration, neck wrinkle treatment, and volumizing fillers.\nAnalysts noted that due to public sentiment, livestreaming sales structure, and competition, the ranking of its flagship brand \"Kefumei\" declined during the Double 11 shopping festival, potentially putting short-term pressure on its skincare business. However, the company's strong brand equity and operational foundation remain intact, with focus on subsequent channel adjustments and new product launches.\nFurthermore, recombinant collagen is recognized for its anti-aging and reparative properties, with strong consumer awareness. Given the company's established presence in the medical aesthetic channel, the newly approved product is expected to contribute to a second growth curve post-launch.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1146543306","isCrawlerRequest":true}